Singapore markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
41.27+0.08 (+0.19%)
At close: 04:00PM EDT
41.13 -0.14 (-0.34%)
After hours: 05:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close41.19
Open40.97
Bid41.18 x 800
Ask41.20 x 1300
Day's range40.90 - 41.54
52-week range40.90 - 58.10
Volume3,893,919
Avg. volume2,901,717
Market cap103.211B
Beta (5Y monthly)0.36
PE ratio (TTM)15.75
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.75 (4.14%)
Ex-dividend date26 May 2022
1y target estN/A
  • Zacks

    Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK

    Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.

  • Financial Times

    Sanofi drops experimental breast cancer drug after second trial fails

    Sanofi has abandoned development of a once-promising breast cancer drug called amcenestrant after a second failed clinical trial, dealing a blow to its pipeline of new treatments. The French pharmaceutical group said on Wednesday that it had stopped all studies of the experimental drug following an analysis of late-stage trial data that showed it did not meet the efficacy threshold. “This was a flagship drug in pipeline and important oncology asset,” wrote Credit Suisse analyst Jo Walton.

  • Zacks

    Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down

    Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.